Aileron Therapeutics Presents New Preclinical Data on Stapled Peptide Inhibitor of Cancer Transcription Factor HIF-1a at American Association for Cancer Research Annual Meeting

Aileron Therapeutics, Inc. today announced new preclinical data demonstrating that ATSP-9172, its Stapled Peptide inhibitor of HIF-1a-dependent transcription, exhibits on-target binding activity, favorable pharmacokinetic properties and potent in vivo efficacy in a human prostate cancer model. These data will be presented today in a late-breaking poster presentation titled, “ATSP-9172, a novel Stapled Peptide inhibitor of HIF-dependent transcriptional activity with in vivo antitumor efficacy in a preclinical model of prostate cancer,” at the American Association for Cancer Research (AACR) Annual Meeting 2013, abstract number LB-304.

Back to news